Mark J. Alles - 16 Sep 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: Director
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol: SYRS
Transactions as of: 16 Sep 2023
Net transactions value: $0
Form type: 4
Filing time: 19 Sep 2023, 16:47:30 UTC
Previous filing: 02 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Options Exercise		+2,666	+267%		3,666	16 Sep 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRS	Restricted Stock Units	Options Exercise	$0	-2,666	-33%	$0.000000	5,334	16 Sep 2023	Common Stock	2,666		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon vesting of a restricted stock unit award.
F2	On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3	Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F4	Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.